07.11.19

Double-Barreled Biologic for Diabetic Retinopathy Emerging

Source: Medscape

Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a report in Medscape.

Phase 2 results from the BOULEVARD trial (NCT02699450), which is comparing faricimab, the first biologic to target both the Ang-2 and VEGF pathways, with ranibizumab, will be presented at the American Society of Retina Specialists (ASRS) 2019 Annual Meeting. The drug, from Roche and Genentech, is currently in phase 3 trials.

“We’re all very interested to see if we have a drug that can be used less frequently than every 8 weeks but with outcomes similar to monthly therapy, and whether the improvement in acuity gains, compared with ranibizumab (Lucentis, Genentech), is replicated in phase 3,” said Lloyd Clark, MD, from the Palmetto Retina Center in West Columbia, South Carolina.

Read the full story.

Related Content